Strategic Alliances Leverage recent partnerships with SGD Pharma and Vance Street Capital to position Prince as a preferred sterilization and packaging partner for North American pharma and medical device manufacturers seeking integrated supply chain solutions.

Nasal Vial Opportunity Capitalize on the launch of sterile Type I glass nasal vials for the US market by targeting chronic condition therapeutics and nasal administration devices that require validated sterilization and depyrogenation capabilities.

Low-Temp Sterilization Promote in‑house low-temperature hydrogen peroxide sterilization as a differentiator for sensitive medical devices and biologics packaging, appealing to customers seeking alternatives to EtO with shorter cycle times and reduced regulatory burden.

WFI Excellence Highlight water for injection washing capabilities to reduce bioburden and endotoxins on components such as seals, stoppers, and vials, offering a value proposition for manufacturers facing stringent cleanliness and endotoxin standards.

Expansion Readiness Position Prince as a scalable sterilization and depyrogenation partner capable of handling growth in pharmaceutical and medical device sectors, backed by recent investments and a track record of state‑of‑the‑art cleanroom processing.